KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) Research & Development (2017 - 2026)

Aquestive Therapeutics has reported Research & Development over the past 9 years, most recently at $3.2 million for Q4 2025.

  • For Q4 2025, Research & Development fell 35.0% year-over-year to $3.2 million; the TTM value through Dec 2025 reached $17.2 million, down 15.23%, while the annual FY2025 figure was $17.2 million, 15.23% down from the prior year.
  • Research & Development for Q4 2025 was $3.2 million at Aquestive Therapeutics, down from $4.5 million in the prior quarter.
  • Over five years, Research & Development peaked at $5.9 million in Q1 2024 and troughed at $2.9 million in Q4 2023.
  • A 5-year average of $4.3 million and a median of $4.3 million in 2021 define the central range for Research & Development.
  • Biggest five-year swings in Research & Development: skyrocketed 70.26% in 2024 and later plummeted 35.0% in 2025.
  • Year by year, Research & Development stood at $4.4 million in 2021, then dropped by 2.77% to $4.3 million in 2022, then tumbled by 32.49% to $2.9 million in 2023, then surged by 70.26% to $4.9 million in 2024, then plummeted by 35.0% to $3.2 million in 2025.
  • Business Quant data shows Research & Development for AQST at $3.2 million in Q4 2025, $4.5 million in Q3 2025, and $4.1 million in Q2 2025.